Medivir: MIV-711 Obtains Rare Pediatric Disease Designation and Orphan Drug Designation
Research Note
2024-04-25
11:15
Redeye sees the RPDD and ODD from the FDA as signs that the osteoarthritis programme MIV-711 is moving forward.
RR
Richard Ramanius
Disclosures and disclaimers